BBR3464 is the first congener of a novel group of platinum compounds, the so-called cationic trinuclear platins. It binds to DNA more rapidly than cisplatin, which results in long-range interstrand and intrastrand cross-links. It is more potent than cisplatin, and very low dosages were effective in phase I trials. With a 1-hour intravenous infusion of 1.1 mg/m2 every 28 days, diarrhea (preceded by abdominal cramps), nausea/vomiting, and neutropenia were the most prominent drug-related adverse effects. There were no signs of drug-related nephrotoxicity, neurotoxicity, or lung dysfunction (12R, 13r, 31r).
Was this article helpful?
Do You Suffer From High Blood Pressure? Do You Feel Like This Silent Killer Might Be Stalking You? Have you been diagnosed or pre-hypertension and hypertension? Then JOIN THE CROWD Nearly 1 in 3 adults in the United States suffer from High Blood Pressure and only 1 in 3 adults are actually aware that they have it.